Panackel Charles, Raja Kaiser, Fawas Mohammed, Jacob Mathew
Aster Integrated Liver Care, Aster Medcity, Kochi, India.
King's college hospital, Dubai, UK.
Best Pract Res Clin Gastroenterol. 2024 Dec;73:101957. doi: 10.1016/j.bpg.2024.101957. Epub 2024 Nov 14.
Acute liver failure (ALF) is a rare and dynamic syndrome occurring as a sequela of severe acute liver injury (ALI). Its mortality ranges from 50% to 75% based on the aetiology, patients age and severity of encephalopathy at admission. With improvement in intensive care techniques, transplant-free survival in ALF has improved over time. Timely recognition of patients who are unlikely to survive with medical intervention alone is crucial since these individuals may rapidly develop multiorgan failure and render liver transplantation futile. Various predictive models, biomarkers and AI-based models are currently used in clinical practice, each with its fallacies. The King's College Hospital criteria (KCH) were initially established in 1989 to identify patients with acute liver failure (ALF) caused by paracetamol overdose or other causes who are unlikely to improve with conventional treatment and would benefit from a liver transplant. Since then, various models have been developed and validated worldwide. Most models include age, aetiology of liver disease, encephalopathy grade, and liver injury markers like INR, lactate, factor V level, factor VIII/V ratio and serum bilirubin. But none of the currently available models are dynamic and lack accuracy in predicting transplant free survival. There is an increasing interest in developing prognostic serum biomarkers that when used alone or in combination with clinical models enhance the accuracy of predicting outcomes in ALF. Genomics, transcriptomics, proteomics, and metabolomics as well as machine learning and artificial intelligence (AI) algorithms are areas of interest for developing higher-precision predictive models. Overall, the future of prognostic models in ALF is promising, with ongoing research paving the way for more accurate, personalized, and dynamic risk assessment tools that can potentially save lives in this challenging condition. This article summarizes the history of prognostic models in ALF and future trends.
急性肝衰竭(ALF)是一种罕见的动态综合征,是严重急性肝损伤(ALI)的后遗症。根据病因、患者年龄和入院时肝性脑病的严重程度,其死亡率在50%至75%之间。随着重症监护技术的进步,ALF患者不进行肝移植的生存率随时间有所提高。及时识别那些仅通过医学干预不太可能存活的患者至关重要,因为这些患者可能迅速发展为多器官功能衰竭,从而使肝移植变得徒劳。目前临床实践中使用了各种预测模型、生物标志物和基于人工智能的模型,但每种都有其缺陷。国王学院医院标准(KCH)最初于1989年制定,用于识别由对乙酰氨基酚过量或其他原因引起的急性肝衰竭(ALF)患者,这些患者不太可能通过传统治疗改善,而将从肝移植中获益。从那时起,世界各地开发并验证了各种模型。大多数模型包括年龄、肝病病因、肝性脑病分级以及诸如国际标准化比值(INR)、乳酸、凝血因子V水平、凝血因子VIII/V比值和血清胆红素等肝损伤标志物。但目前可用的模型都不是动态的,在预测不进行肝移植的生存率方面缺乏准确性。开发预后血清生物标志物的兴趣与日俱增,这些生物标志物单独使用或与临床模型结合使用时,可提高预测ALF预后的准确性。基因组学、转录组学、蛋白质组学和代谢组学以及机器学习和人工智能(AI)算法是开发更高精度预测模型的关注领域。总体而言,ALF预后模型的未来充满希望,正在进行的研究为更准确、个性化和动态的风险评估工具铺平了道路,这些工具可能在这种具有挑战性的情况下挽救生命。本文总结了ALF预后模型的历史和未来趋势。